Trial results offer hope of a more effective and tolerable treatment option to manage lupus-related kidney disease.
News & Stories
One of our key goals is to ensure people with lupus have access to the care and treatments they need. Recently, access to a few vital treatments has been challenging to obtain, specifically access to quinacrine, hydroxychloroquine, and Benlysta®.
For people with chronic illnesses like lupus, affording monthly medications can be a struggle. Knowing your options can help when it comes to navigating the process of applying for funding assistance.
Lupus organizations announce groundbreaking collaborative initiative to inform lupus drug development.
Ask The Experts: Dr. Emily Von Scheven presents on steroid use in children with lupus
Fans may be surprised she mentions that she has received chemotherapy for her lupus.
An October 2015 update from Health Educator Sarah Stothers, RN, BS, for options on how to make medications like hydroxychloroquine more affordable.
Off-label drugs for the treatment of lupus symptoms represents the standard of care for people with lupus, but current regulations make it difficult for doctors and manufacturers to communicate. Read Sandra C. Raymond's remarks now.
Further studies may lead to interventions that improve the health outcomes of people with lupus.
Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO
June 2015 - Dr. Elisabet Svenungsson answered your questions about antiphospholipid syndrome and lupus anticoagulant.
Lupus is an autoimmune disease in which people generate antibodies against their own organs. But when antibodies to phospholipid-binding proteins are involved, a variety of complications can occur.
The Lupus Nephritis Trials Network (LNTN) is a worldwide organization that brings researchers together with the shared goal of improving outcomes for patients with lupus nephritis.
The Lupus Foundation of America Corporate Advisory Council provides industry perspective helping identify and address barriers to lupus drug development.
Although it is recommended that people with lupus receive most standard vaccinations, no specific recommendations exist with respect to how the new biologic medications may affect the safety and efficacy of these vaccinations. Learn more.
Flare rates among participants receiving a low dose of the b-cell blocker did not meet primary endpoint but were lower for individuals receiving a higher dose.
Why women should ask questions early about reproductive planning
Learn how you can be proactive about protecting your sight
Results from a small pilot study provide hope that lupus disease activity can be suppressed in children with lupus. Read more.
Kim Cantor, Lupus Foundation of America’s Senior Director of Public Policy and Government Relations, discusses the Foundation’s Medicare for Patients RX (MAPRx) Coalition
Lupus Foundation of America medical director Dr. Joan Merrill discusses a recently completed a study that may help to improve the design for future lupus clinical trials and secure approval of new safe and more tolerable treatments for lupus.
In her Expert Column, Dr. Joan T. Merrill, Medical Director, explains why antimalarial medicines are now used to treat lupus.
Ask the Expert: Dr. Betsy Blazek O'Neill discusses complementary medicines and lupus
According to research presented this week at the American College of Rheumatology Annual Meeting, researchers have identified three potentially modifiable risk factors and one protective medication that may improve the health of people living with lupus.
Researchers from the University of California and Brigham and Women’s Hospital in Boston recently examined adherence among Medicaid beneficiaries with lupus to prescribed medications and found the patients were not following treatment plans, putting themselves at risk for poor outcomes.
The Health Insurance Marketplace offers coverage to many Americans who currently do not have health insurance. We have gathered relevant links to help you locate the information you need to know.
New study reinforces need for Patients’ Access to Treatments Act (H.R. 460) to reduce excessive financial burden placed on people with chronic diseases
People with lupus who were treated with hydroxychloroquine (HCQ), an anti-malarial drug, early after a diagnosis of lupus had less cumulative organ damage at three years after diagnosis than those who did not receive HCQ, according to a new analysis.
After more than a half-century of drought, many new treatments are in development for lupus. However, approval of a new treatment does not ensure that all people with lupus will be able to try it.
A new study sheds light on the specific effects of drug treatments versus disease activity as risk factors for lymphoma, a type of cancer, among people with lupus.
Our national lupus research program aggressively seeks to advance the science and medicine of lupus and to improve the quality of life for all people affected by lupus.
The results of this study indicate that current use of steroids (20 mg/day or more) is perhaps the most significant risk factor for heart disease in individuals with lupus.
The Lupus Foundation of America is calling on the Department of Health and Human Services to ensure that people with chronic diseases get access to medications.
Dr. Murray Urowitz discusses current and potential new therapies for managing lupus.
Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity.
People with lupus are at increased risk of cardiovascular disease, especially when taking steroids. The use of anti-malarial drugs, such as hydroxychloroquine, significantly reduces this risk.
This study examined the long-term safety of belimumab over a 4-year period in people with lupus. The results highlight the long-term safety of belimumab over a 4-year period.
If your luggage is exposed to extreme temperatures or humidity, your medications could lose potency and effectiveness.
Dr. Richard Furie of the North Shore-Long Island Jewish Health System provides an overview of how lupus is treated.
Lupus Foundation of America Medical Director Dr. Joan Merrill provides an overview of lupus and its health effects.
The findings highlight specific kinds of changes in lupus biomarkers that are most associated with effective use of belimumab in the treatment of lupus.
The researchers hoped to learn about the safety and efficacy of atorvastatin (Lipitor®) in reducing cholesterol in children with lupus.
The New England Journal of Medicine published results from a long-term study for the treatment of lupus nephritis.
Dr. Emily von Scheven of the University of California at San Francisco discusses the development of consensus treatment plans for proliferative nephritis in juvenile systemic lupus.
Dr. Michelle Petri of the Johns Hopkins University Medical Center discussed the results of a study of vitamin D supplementation in people with lupus.
National lupus organizations, and individuals with lupus and their families around the world, are rallying to protect access to new treatments of lupus.
Health Canada and European Regulators have approved BENLYSTA™.
Don’t make your lupus worse by ignoring your doctor’s instructions—take your medications as prescribed. And if there is some reason you aren’t taking them, talk to your doctor or pharmacist. Help them to help you!
The approval of Benlysta—the first lupus drug in more than 50 years—ushers in a new era of treatment.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA®.
The U.S. Food and Drug Administration (FDA) approved the drug, BENLYSTA®, for the treatment of lupus, an autoimmune disease.
Human Genome Sciences and GlaxoSmithKline announced publication of the BLISS-52 study of BENLYSTA®.
Epratuzumab is an investigational agent for the treatment of lupus. The researchers hoped to learn whether epratuzumab could be a safe and effective treatment for people with moderate-to-severe lupus.
There are a number of treatments used for lupus nephritis, but none of them are approved by the U.S. Food and Drug Administration (FDA). The researchers hoped to compare the efficacy and safety of MMF and azathioprine as maintenance therapy.
The researchers hoped to learn whether treatment with belimumab could reduce the use of steroids in people with active lupus.
The researchers hoped to learn whether there are any tests that could predict low blood sugar in women with lupus taking hydroxychloroquine.
Keeping track of your medications, and taking them correctly, can feel overwhelming. Learn more about how to get the most out of your medications.
Dr. Isenberg discusses several of the new agents under evaluation for lupus and looks to ways lupus treatment will change with evolving technology and new scientific findings.
The researchers hoped to learn what factors have an impact on how much time it takes for a lupus patient to develop skin damage.
The researchers hoped to determine the risk of developing blood clots in people with lupus, while factoring in the year of diagnosis and disease severity.
The researchers wanted to compare the effectiveness of mycophenolate mofetil (CellCept) with that of azathioprine to prevent kidney flares after the initial treatment for nephritis was successful.
The researchers hoped to learn about the safety and potential effectiveness of belimumab in the treatment of lupus.
Hydroxychloroquine belongs to the family of medicines called “antimalarials” (AMs), which are also classified as disease-modifying anti-rheumatic drugs, or DMARDs. These drugs were initially used to prevent and to treat malaria but are no longer used for those purposes.
Dr. David Wofsy of the University of California, San Francisco, leads a discussion and takes questions about being newly diagnosed and living with lupus.
This trial was the first stage of testing for rontalizumab, which is a new treatment that interferes with an inflammatory protein called "interferon-alpha."
Please join us for our inaugural Lupus Awareness Night with the Miami Dolphins. Come and spend the afternoon with us as we watch the Miami Dolphins play against the San Francisco 49ers while raising awareness!
We invite you to join us at Anthony's Coal Fired Pizza in Coral Gables for our Pizza with a Purpose Fundraiser! Bring along your friends and family to celebrate the upcoming Walk to End Lupus Now in Miami- Florida's largest lupus walk!
La Fundacion Americana de Lupus, Capitulo de Florida les invita a participar en la caminata mas grande de lupus de la Florida para recaudar fondos y levantar el conocimiento sobre lupus.
Join us to learn how to optimize your health with evidence based tools.
Join us to learn about how dental health relates to lupus and managing symptoms.
We invite you to join us at Chipotle for a night out for lupus! Bring along your friends and family to celebrate the upcoming Walk to End Lupus Now in Miami – Florida’s largest lupus walk!
Join us at Marlins Park for 2016 Walk to End Lupus Now! Come and spend your afternoon at the ballpark while helping us raise awareness!
The Living Well With Lupus Symposium provides information and strategies to help you live well with lupus.
This educational teleconference will address complications, medical evaluation and treatment as it relates to kidney involvement in lupus.
Please join us for our Living Well with Lupus Seminar in Orlando.
Thank you Palm Beach for coming out to Walk to End Lupus Now. You have until July 5 to turn in your donations and help us reach our goal.
Thank you Orlando for coming out to Walk to End Lupus Now. You have until June 21 to turn in your donations and help us reach our goal.
Thank you Jacksonville for coming out to Walk to End Lupus Now. You have until April 13 to turn in your donations and help us reach our goal.
Are you interested in starting a group in your area or becoming a co-facilitator of an exisiting group? If, so we invite you to attend our next facilitator training.
Thank you for Melbourne for coming out to Walk to End Lupus Now. You have until December 14 to turn in your donations and help us reach our goal.
Thank you for Miami for coming out to Walk to End Lupus Now. You have until November 30 to turn in your donations and help us reach our goal.
Join us for our third annual Southwest Florida Walk to end Lupus now in Naples. Lets rally together to create awareness of lupus while raising funds to fight this terrible disease.
We are heading back to the Palm Beach Zoo for our South Florida Spring Walk to End Lupus Now! Please join us as we rally together to create awareness of lupus while raising funds to fight this terrible disease.
NEW in 2015! The Walk to End Lupus Now is coming to Northern Florida in Jacksonville. Join us as we rally together to create awareness of lupus while raising funds to fight this terrible disease.
What you need to know to help with issues surrounding disability.
Join us for the SLE Self Help Leader Training - a two day training course designed to prepare people to teach others with lupus how to take a more active part in their health care and live better despite lupus.
Patients, caregivers, and the medical community are invited to join us for a day devoted to those affected by lupus. The Annual NC Lupus Summit is the largest educational conference on lupus in the state and provides a variety of discussions led by physicians and other experts dedicated to solving the cruel mystery of lupus.While lupus can be a moving target, this year's summit will help you aim your focus on targeting your health.
Help us solve the cruel mystery!
Join us to learn about current treatments methods and new options that are up and coming.
The Lupus Foundation of America, Wisconsin Chapter will host a Lupus Medical Symposium on Saturday, May 2, 2015 at Froedtert Hospital, Dean Roe Auditorium from 1:00 PM to 3:00 PM. We welcome Andreea Antonescu-Turcu, MD who will present "Sleep Disorders and Lupus". We also welcome Mary Cronin, MD who will present a general explanation "What is Lupus?". We encourage newly diagnosed patients and their supporters to this important presentation.
This seminar will provide information on 2 different topics: Lupus and the Musculoskeletal System and Complementary and Alternative Medicine.
Feel empowered to advocate for yourself on a social and political level to overcome healthcare barriers.